Literature DB >> 23707207

Investigation of the absorbed and metabolized components of Danshen from Fuzheng Huayu recipe and study on the anti-hepatic fibrosis effects of these components.

Tao Yang1, Dan-Ping Shen, Qin-Lan Wang, Yan-Yan Tao, Cheng-Hai Liu.   

Abstract

ETHNOPHARMACOLOGY: Fuzheng Huayu recipe (FZHY) was formulated on the basis of Chinese medicine theory in treating liver fibrosis. It has a significant efficacy against liver fibrosis caused by chronic hepatitis B, with the action mechanisms of inhibition of hepatic stellate cell activation, protection of hepatocyte oxidative injury and regulations of hepatic matrix remodeling etc. AIM OF THE STUDY: To identify the absorbed components and metabolites of Danshen in FZHY in rat serum, and find their active components for anti-liver fibrosis.
MATERIAL AND METHODS: A valid high performance liquid chromatography-electrospray ionization ion trap mass spectrometry (HPLC-ESI/MS(n)) method was established to investigate the absorbed and metabolized compounds of Danshen in FZHY in rat serum after oral administration. Mass spectra were acquired in both negative and positive modes. Otherwise, to evaluate the anti-hepatic fibrosis efficacies of absorbed and metabolized compounds, the LX-2 cell line of hepatic stellate cell (HSC), which was crucial cellular basis of fibrogenesis, was cultured and incubated with absorbed compounds, the cytotoxicity was determined with the cellomics Multiparameter Cytotoxicity Kit 1 by High Content Screening (HCS), the cell proliferation was assayed with EdU-DNA incorporation, and the cell activation was analyzed through α-smooth muscle actin (α-SMA) expression with high content screening technology.
RESULTS: More than 11 compounds and 2 metabolites from Danshen were identified in the serum after oral administration of FZHY by comparing their mass spectra and retention behavior with reference compounds or literature data. Among these compounds, there were no obvious changes in nuclear morphology, membrane permeability with blow 96 μM of six polar compounds treatment in comparison with control cells, respectively. And the salvianolic acid B (6 μM, 48 μM), caffeic acid (6 μM, 48 μM) and rosmarinic acid (48 μM) could obviously inhibit LX-2 cells proliferation, down-regulate α-SMA expression.
CONCLUSION: The results proved that the established method could be applied to analyze the absorbed into blood compounds of Danshen after oral administration FZHY. These absorbed compounds included 11 compounds and 2 metabolites of Danshen. Among them, the salvianolic acid B, caffeic acid and rosmarinic acid were the effective components of FZHY to anti-hepatic fibrosis effects.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23707207     DOI: 10.1016/j.jep.2013.05.031

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  14 in total

1.  Salvianolic Acid B Enhances Hepatic Differentiation of Human Embryonic Stem Cells Through Upregulation of WNT Pathway and Inhibition of Notch Pathway.

Authors:  Jiamei Chen; Benjamin Tschudy-Seney; Xiaocui Ma; Mark A Zern; Ping Liu; Yuyou Duan
Journal:  Stem Cells Dev       Date:  2018-01-23       Impact factor: 3.272

2.  Enhancement of brain-targeting delivery of danshensu in rat through conjugation with pyrazine moiety to form danshensu-pyrazine ester.

Authors:  Ailing Hui; Huayang Yin; Zheng Zhang; An Zhou; Jingchao Chen; Li Yang; Zeyu Wu; Wencheng Zhang
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

3.  The Active Compounds of Yixin Ningshen Tablet and Their Potential Action Mechanism in Treating Coronary Heart Disease- A Network Pharmacology and Proteomics Approach.

Authors:  Xing Lv; Huijun Wang; Ruoming Wu; Xiaoyan Shen; Guan Ye
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-25       Impact factor: 2.629

4.  Simultaneous determination of eight analytes of Fuzheng Huayu recipe in beagle dog plasma by UHPLC-Q/exactive Orbitrap HRMS and its application to toxicokinetics.

Authors:  Yu-Lin Wang; Ming-Jv Yang; Rong-Sheng Li; Ye-Qing Hu; Yi-Feng Pan; Tao Yang
Journal:  Biomed Chromatogr       Date:  2022-01-22       Impact factor: 1.911

5.  Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis.

Authors:  Yan-yan Tao; Xiu-chuan Yan; Tao Zhou; Li Shen; Zu-long Liu; Cheng-hai Liu
Journal:  BMC Complement Altern Med       Date:  2014-11-18       Impact factor: 3.659

6.  Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis.

Authors:  Qilong Chen; Feizhen Wu; Mei Wang; Shu Dong; Yamin Liu; Yiyu Lu; Yanan Song; Qianmei Zhou; Ping Liu; Yunquan Luo; Shibing Su
Journal:  Int J Mol Sci       Date:  2016-06-03       Impact factor: 5.923

7.  Dynamical Regulation Analysis Identifies Molecular Mechanisms of Fuzheng-Huayu Formula against Hepatitis B-Caused Liver Cirrhosis.

Authors:  Qi-Long Chen; Yi-Yu Lu; Jing-Hua Peng; Shu Dong; Bin Wei; Ya-Nan Song; Qian-Mei Zhou; Hui Zhang; Ping Liu; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-28       Impact factor: 2.629

Review 8.  Curative Effects of Fuzheng Huayu on Liver Fibrosis and Cirrhosis: A Meta-Analysis.

Authors:  Shu Dong; Qi-Long Chen; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-28       Impact factor: 2.629

9.  Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu.

Authors:  Jiamei Chen; Wei Gao; Ping Zhou; Xiaocui Ma; Benjamin Tschudy-Seney; Chenghai Liu; Mark A Zern; Ping Liu; Yuyou Duan
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

10.  Neuroprotective Effect of Salvianolic Acids against Cerebral Ischemia/Reperfusion Injury.

Authors:  Shuai Hou; Ming-Ming Zhao; Ping-Ping Shen; Xiu-Ping Liu; Yuan Sun; Jia-Chun Feng
Journal:  Int J Mol Sci       Date:  2016-07-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.